|
|
Volumn 103, Issue 14, 2011, Pages 1079-1082
|
|
Beyond ipilimumab: new approaches target the immunological synapse.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
APOPTOSIS REGULATORY PROTEIN;
CD40 ANTIGEN;
GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR;
IPILIMUMAB;
LEUKOCYTE ANTIGEN;
MDX 1106;
MDX-1106;
MONOCLONAL ANTIBODY;
OX40 LIGAND;
PDCD1 PROTEIN, HUMAN;
PROGRAMMED DEATH 1 RECEPTOR;
TNFRSF18 PROTEIN, HUMAN;
TNFSF4 PROTEIN, HUMAN;
DRUG APPROVAL;
DRUG EFFECT;
HUMAN;
IMMUNOLOGICAL SYNAPSE;
IMMUNOLOGY;
IMMUNOTHERAPY;
LYMPHOCYTE ACTIVATION;
MELANOMA;
METHODOLOGY;
NEOPLASM;
NOTE;
PHASE 3 CLINICAL TRIAL (TOPIC);
SKIN TUMOR;
T LYMPHOCYTE;
ANTIBODIES, MONOCLONAL;
ANTIGENS, CD;
ANTIGENS, CD40;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
APOPTOSIS REGULATORY PROTEINS;
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG APPROVAL;
GLUCOCORTICOID-INDUCED TNFR-RELATED PROTEIN;
HUMANS;
IMMUNOLOGICAL SYNAPSES;
IMMUNOTHERAPY;
LYMPHOCYTE ACTIVATION;
MELANOMA;
NEOPLASMS;
OX40 LIGAND;
PROGRAMMED CELL DEATH 1 RECEPTOR;
SKIN NEOPLASMS;
T-LYMPHOCYTES;
|
|
EID: 84855520895
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djr281 Document Type: Note |
|
Times cited : (29)
|
|
References (0)
|
